Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Network of interactions between the tumor necrosis factor superfamily members and small S100 proteins. | PLoS One | 2026 | 42809589 | PubTator, text mining | PubMed |
| Cord Blood-Derived Fibroblast Activation Protein-Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo. | Cancer Sci | 2026 | 42764195 | PubTator, text mining | PubMed |
| Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B-Cell Lymphoma With Bulky Disease. | Cancer Med | 2026 | 42702822 | PubTator, text mining | PubMed |
| Single-cell multiomics reveals exosome-mediated reprogramming and clonotypic remodeling of T cells in triple-negative breast cancer. | Signal Transduct Target Ther | 2026 | 42618562 | PubTator, text mining | PubMed |
| A PD1-CD137L Fusion Protein More Potently Enhances Anti-Tumour Immune Responses Than Targeting PD-L1 and CD137 Separately. | Immunology | 2026 | 42572505 | PubTator, text mining | PubMed |
| Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion. | bioRxiv | 2026 | 42538952 | PubTator, text mining | PubMed |
| Assessment of the Novel rVSV-PD-1-4-1BBL Oncolytic Activity on Mouse and Human Cancer Cell Lines. | Biomedicines | 2026 | 42511949 | PubTator, text mining | PubMed |
| 4-1BBL Suppresses Anti-Inflammatory Responses by Regulating Metabolic Reprogramming of Macrophages. | Immunology | 2026 | 42504467 | PubTator, text mining | PubMed |
| Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial. | Nat Med | 2026 | 42463852 | PubTator, text mining | PubMed |
| CD137 in cancer therapy - bench to bedside. | Immunotherapy | 2026 | 42427082 | PubTator, text mining | PubMed |
| Clinical significance of CD161+CD8+ T cells in the tumor microenvironment of esophageal squamous cell carcinoma and their association with the 4-1BB signaling pathway. | J Immunother Cancer | 2026 | 42425714 | PubTator, text mining | PubMed |
| Vaccination with an HSV-1 virus containing CD-137L reduces herpetic corneal disease when used both prophylactically and therapeutically. | Virus Res | 2026 | 42379378 | PubTator, text mining | PubMed |
| Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity. | Cancers (Basel) | 2026 | 42279415 | PubTator, text mining | PubMed |
| Non-classical immune checkpoint CD137/CD137L and CD200/CD200R expressions are regulated by the tumor immune microenvironment in lymph node aspirates from lung cancer patients. | Front Immunol | 2026 | 42273703 | PubTator, text mining | PubMed |
| mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac). | Mol Ther Oncol | 2026 | 42256207 | PubTator, text mining | PubMed |
| Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications. | Cell Rep Methods | 2026 | 42143016 | PubTator, text mining | PubMed |
| A novel mRNA-based therapeutic vaccine elicits robust anti-tumor immunity against HPV-associated malignancies. | Front Immunol | 2026 | 42079630 | PubTator, text mining | PubMed |
| De novo masking domains that gate TNF-family ligand assembly and activity. | bioRxiv | 2026 | 42079277 | PubTator, text mining | PubMed |
| Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents. | Front Immunol | 2026 | 41948319 | PubTator, text mining | PubMed |
| Armed oncolytic adenovirus elicits a "self-feeder" effect to supercharge NK cells for solid tumor control. | Cell Immunol | 2026 | 41932099 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers